Related Experiment Video
Updated: Dec 22, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
A novel neurodegenerative spectrum disorder in patients with MLKL deficiency
Soren L Faergeman1,2,3, Hayley Evans1,2, Kathrine E Attfield1,2
1Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DS, UK.
Abstract:
Mixed lineage kinase domain-like (MLKL) is the main executor of necroptosis, an inflammatory form of programmed cell death. Necroptosis is implicated in combating infections, but also in contributing to numerous other clinical conditions, including cardiovascular diseases and neurodegenerative disorders. Inhibition of necroptosis is therefore of therapeutic interest. Here we report two siblings both of whom over the course of 35 years developed a similar progressive, neurodegenerative spectrum disorder characterized by paresis, ataxia and dysarthria. Magnetic resonance imaging of their central nervous system (CNS) revealed severe global cerebral volume loss and atrophy of the cerebellum and brainstem. These brothers are homozygous for a rare haplotype identified by whole genome sequencing carrying a frameshift variant in MLKL, as well as an in-frame deletion of one amino acid in the adjacent fatty acid 2-hydroxylase (FA2H) gene. Functional studies of patient-derived primary cells demonstrated that the variant in MLKL leads to a deficiency of MLKL protein resulting in impairment of necroptosis. Conversely, shotgun lipidomic analysis of the variant in FA2H shows no impact on either the abundance or the enzymatic activity of the encoded hydroxylase. To our knowledge, this is the first report of complete necroptosis deficiency in humans. The findings may suggest that impaired necroptosis is a novel mechanism of neurodegeneration, promoting a disorder that shares some clinical features with primary progressive multiple sclerosis (PPMS) and other neurodegenerative diseases. Importantly, the necroptotic deficiency does not cause symptoms outside the nervous system, nor does it confer susceptibility to infections. Given the current interest in pharmacological inhibition of necroptosis by targeting MLKL and its associated pathways, this strategy should be developed with caution, with careful consideration of the possible development of adverse neurological effects.
Insights
Complete deficiency in programmed cell death (necroptosis) due to MLKL variants causes a progressive neurodegenerative disorder in humans. This finding suggests caution for therapeutic necroptosis inhibition, highlighting potential neurological side effects.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Background:
- Necroptosis, an inflammatory programmed cell death executed by MLKL, is involved in infection control and various diseases.
- Therapeutic inhibition of necroptosis is being explored for clinical applications.
- Neurodegenerative disorders represent a significant unmet medical need.
Purpose of the Study:
- To investigate the clinical and molecular basis of a novel neurodegenerative disorder in two siblings.
- To determine the functional consequences of identified genetic variants in MLKL and FA2H.
- To explore the role of necroptosis deficiency in human neurodegeneration.
Main Methods:
- Whole genome sequencing to identify genetic variants.
- Functional studies using patient-derived primary cells to assess MLKL deficiency and necroptosis impairment.
- Shotgun lipidomic analysis to evaluate FA2H function.
- Clinical and neuroimaging assessments (MRI) of affected siblings.
Main Results:
- Two siblings with a progressive neurodegenerative disorder (paresis, ataxia, dysarthria) were identified.
- Homozygosity for a rare haplotype revealed a frameshift variant in MLKL and an in-frame deletion in FA2H.
- Patient cells showed impaired necroptosis due to MLKL deficiency; FA2H function was unaffected.
- This represents the first report of complete necroptosis deficiency in humans.
Conclusions:
- Impaired necroptosis due to MLKL deficiency is a novel mechanism contributing to a spectrum of neurodegenerative disease.
- The disorder shares features with primary progressive multiple sclerosis and other neurodegenerative conditions.
- Therapeutic strategies targeting MLKL for necroptosis inhibition warrant caution due to potential adverse neurological effects.
Related Concept Videos
Parkinson's Disease: Overview
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

